Amicus Therapeutics, Inc. (NASDAQ:FOLD)

CAPS Rating: 2 out of 5

A clinical-stage biopharmaceutical company, which focused on the discovery, development and commercialization of novel small molecule, orally-administered drugs, known as pharmacological chaperones, for the treatment of a range of human genetic diseases.

Recs

2
Player Avatar zzlangerhans (99.80) Submitted: 3/29/2014 2:32:27 PM : Outperform Start Price: $2.17 FOLD Score: +181.09

I've sort of given up on Amicus myself after following them for seven years and not seeing any signs of success or impending success in clinical trials of their small molecule "chaperones" for lysosomal storage diseases. In 2012 the company got slapped down from their latest stab at legitimacy with weak six month data from Study 011 phase III trial of migalastat for Fabry's disease. Twelve month data should have been released last June, but the company kept pushing the data release back and now they're saying they will release 12 and 24 month data together next quarter. Huh? Obviously the 12 month data are bad and they're hoping the 24 month data will bail them out.

I just need to register my skepticism before copping to the fact that I have 4000 shares with a cost basis of 2.33, mostly due to a recent buy of 3000 shares. Portefeuille likes to play Amicus and he's had great success to date, so I'm rolling with him on this one. In addition, topline 18 month data from a European phase III trial of migalastat is expected in H2 2014. If these trials fail, the market cap may slip under a buck as Amicus falls back on early stage trials of migalastat/ERT to maintain a raison d'etre.

Featured Broker Partners


Advertisement